Zevra Therapeutics, Inc. (ZVRA) Stock Price & Analysis
Zevra Therapeutics, Inc. (ZVRA) rose 12.99% to USD 13.66 as of June 9, 2026 at 23:39 UTC, according to Nexqual real-time market data.
ZVRA last closed at USD 12.09; the session ranged USD 12.45–13.8 on volume of 4,987,711 shares. Market capitalization is $807.51M, with a 52-week range of USD 7.16–13.8 (NMS). Source: Nexqual, June 9, 2026 at 23:39 UTC.
Key Statistics (as of June 9, 2026 at 23:39 UTC)
| Price | USD 13.66 |
|---|---|
| Change | ▲ 12.99% (up) |
| Previous Close | USD 12.09 |
| Open | USD 12.45 |
| Day Range | USD 12.45 – 13.8 |
| 52-Week Range | USD 7.16 – 13.8 |
| Volume | 4,987,711 shares |
| Market Cap | $807.51M |
| Exchange | NMS |
Technical Analysis (ZVRA)
Nexqual's technical model rates ZVRA "BUY" based on 5 bullish and 3 bearish signals across 124 daily candles, as of June 9, 2026 at 23:39 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.28 (overbought) |
| vs SMA50 | Above (USD 10.47) |
| MACD | 0.45 (positive) |
Analyst Ratings (ZVRA)
Wall Street analysts rate ZVRA "Strong Buy" based on 9 analysts, with a mean price target of USD 23 (range USD 18–26), per Nexqual as of June 9, 2026 at 23:39 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 23 |
| High Target | USD 26 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (ZVRA)
| Next Earnings Date | 2026-05-06 |
|---|---|
| EPS Estimate | USD 0.17 |
| Revenue Estimate | $34.06M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.18 vs est 0.08 ▲ beat |
| 2025-12-31 | USD 0.19 vs est 0.05 ▲ beat |
| 2025-09-30 | USD -0.01 vs est -0.02 ▲ beat |
| 2025-06-30 | USD -0.06 vs est 1.38 ▼ miss |
Source: Nexqual, June 9, 2026 at 23:39 UTC.
Financials & Fundamentals (ZVRA)
| Total Revenue | $122.29M |
|---|---|
| Revenue Growth (YoY) | +77.50% |
| Gross Margin | +86.07% |
| Operating Margin | +24.38% |
| Profit Margin | +101.58% |
| ROE | +100.65% |
| Debt / Equity | 0.56 |
| Current Ratio | 4.89 |
| Total Cash | $200.62M |
| Total Debt | $1.15M |
| Free Cash Flow | $25.85M |
Source: Nexqual, June 9, 2026 at 23:39 UTC.
Financial Health Score (ZVRA)
Nexqual rates Zevra Therapeutics, Inc.'s overall financial health "Strong" across five dimensions, as of June 9, 2026 at 23:39 UTC.
| Growth | Strong — Revenue +351% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 86%, operating 24% |
| Balance Sheet | Strong — $201M cash vs $1M debt, net cash position |
| Cash Flow | Strong — FCF $26M, 24% margin |
| Efficiency | Strong — ROE 101%, ROA 2.8% |
Ownership (ZVRA)
| Insider Ownership | +1.28% |
|---|---|
| Institutional Ownership | +70.73% |
| Shares Outstanding | 59.12M |
| Float | 54.96M |
| Short % of Float | +7.60% |
Source: Nexqual, June 9, 2026 at 23:39 UTC.
Leadership (ZVRA)
Zevra Therapeutics, Inc. is led by Neil F. McFarlane (age 52), President, CEO & Director, per Nexqual as of June 9, 2026 at 23:39 UTC.
| President, CEO & Director | Neil F. McFarlane (age 52) |
|---|---|
| CFO & Treasurer | Justin A. Renz (age 53) |
| Vice President of Investor Relations & Corporate Communications | Nichol L. Ochsner |
| Senior Vice President of Manufacturing | Christopher M. Lauderback (age 50) |
| Senior Vice President of Regulatory Affairs & Quality | Gerald J. Orehostky (age 58) |
Major Backers & Investors (ZVRA)
Notable institutional backers of Zevra Therapeutics, Inc. include AIGH Capital Management LLC, Morgan Stanley, ROYCE SMALL-CAP TRUST, INC.-Royce Small-Cap Trust, Inc, according to Nexqual as of June 9, 2026 at 23:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AIGH Capital Management LLC | 27.81% |
| Morgan Stanley | 27.63% |
| ROYCE SMALL-CAP TRUST, INC.-Royce Small-Cap Trust, Inc | 7.21% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| State Street | 44.31% |
| Geode Capital | 31.79% |
| Legal & General Group PLC | 26.96% |
Source: Nexqual, June 9, 2026 at 23:39 UTC.
From Zevra Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)
Partnerships
- In addition, the provisions of our termination agreement with Aquestive Therapeutics ("Aquestive") may delay or prevent a change in control of our company.
- If we overcharge the government in connection with our FSS contract or Tricare Agreement, whether due to a misstated FCP or otherwise, we are required to refund the difference to the government.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ADUR | Aduro Clean Technologies Inc. | USD 16.88 | ▲ 20.4% |
| GLUE | Monte Rosa Therapeutics, Inc. | USD 16.61 | ▲ 1.47% |
| MLYS | Mineralys Therapeutics, Inc. | USD 24.18 | ▲ 2.07% |
| PHAT | Phathom Pharmaceuticals, Inc. | USD 9.82 | ▼ 3.06% |
| TVTX | Travere Therapeutics, Inc. | USD 48.57 | ▲ 6.02% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:39 UTC. This page is informational and not investment advice.